The human neutrophil IL-1β secretory response, in contrast to the CXCL8/IL-8 secretory response decreases as MOI increases. by Florencia Sabbione (4862455)

Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer by Fan-Fan Shang (16953264)

Subjects:

Mitochondrial function decreases in pasture-fed dairy cows during early lactation. by Mercedes García-Roche (6459200)

Additional file 5 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

AMPs are increased in lesional HS, but DCD and other sweat-gland associated proteins are decreased. by Margaret Coates (6058580)

“…<p>(A) Volcano plot showing increased or decreased genes in HS. …”

a Non-reducing SDS-PAGE of test samples and by Vanessa Radtke (1674097)

Retinoic acid decreases intracellular K⁺ in pectoral fin buds via transcriptional activation of the calcineurin inhibitor <i>rcan2</i>. by Xiaowen Jiang (8291814)

The decrease or inhibition of Hsp90 induced REST degradation. by Raúl Orozco-Díaz (7067624)

“…(D) The level of REST dramatically reduced in differentiated SH-SY5Y cells treated with GA (1 μM) or PU-H71 (50 nM) at 24 h. (E) The REST level decreased by GA more than 50% and (F) PU-H71 more than 80%, respectively. …”

HFD induces LDs and decreases ER and mitochondria in nephrocytes. by Aleksandra Lubojemska (10746241)

“…(<b>E</b>) Low and high magnification views of pericardial nephrocytes (dotted outlines) from STD and HFD larvae, showing that HFD decreases mitochondria (marked with anti-ATP5A) and ER (marked with anti-KDEL) but increases LDs (marked with LipidTOX). …”

Molecular dynamics simulations of the three systems (PPARG-MOL000098, PPARG-MOL000354, PPARG-MOL000422) after 50 ns. by Lefei Yu (12274846)

Molecular dynamics simulations of the three systems (TNF-MOL000098, TNF-MOL000354, TNF-MOL000422) after 50 ns. by Lefei Yu (12274846)

Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”

Dose-dependent decreases in cell viability with carboplatin, mitoxantrone, vinblastine, and CBD treatment of canine UC cells. by Jordon M. Inkol (11237604)

Decreased expression of V-ATPase upon the siRNA transfection. by Manisha Naskar (2613763)

Discrimination performance deteriorated as the safe-to-conditioned ΔF decreased. by Chi Chen (67021)

The S75A mutation of LeishIF4E3 leads to a decrease in granule formation in response to PBS starvation and to a reduced interaction with LeishIF4G-4. by Rohit Shrivastava (6459608)

Heart specific RNase Z variants show a mild decrease in longevity and locomotor response. by Ekaterina Migunova (15909887)

Lower insular perfusion in the DAT group compared with the non-DAT group. by Masashi Takeuchi (1930312)

“…In the region of interest-based analysis, decrease extent ratios were higher in the DAT group (N = 12) than in the non-DAT group (N = 38) (D). …”

Image_2_Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease.JPEG by Meijuan Liu (4924417)

“…At the cutoff value of 7.955 μg/mL serum ZAG, the sensitivity and specificity for differentiating patients with PCAD from controls were 50.5 and 78.0%, respectively. The combination of ZAG with other clinical variables including age, gender, BMI, SBP, FBG, TC, HDL-C, Cr, and Urea had significantly improved the diagnosis accuracy with a sensitivity of 82.6%, a specificity of 95.0%, and AUC of 0.957 (95% CI, 0.940–0.975, p < 0.05).…”

Image_1_Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease.JPEG by Meijuan Liu (4924417)

“…At the cutoff value of 7.955 μg/mL serum ZAG, the sensitivity and specificity for differentiating patients with PCAD from controls were 50.5 and 78.0%, respectively. The combination of ZAG with other clinical variables including age, gender, BMI, SBP, FBG, TC, HDL-C, Cr, and Urea had significantly improved the diagnosis accuracy with a sensitivity of 82.6%, a specificity of 95.0%, and AUC of 0.957 (95% CI, 0.940–0.975, p < 0.05).…”